REPLIGEN CORP

RGEN Nasdaq CIK: 0000730272

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 41 SEYON STREET, WALTHAM, MA, 02453
Mailing Address 41 SEYON STREET, WALTHAM, MA, 02453
Phone 7814499560
Fiscal Year End 1231
EIN 042729386

Financial Overview

FY2025

$48.89M
Net Income

Recent SEC Filings

Form Type Date Filed Document
DEF 14A Definitive proxy statement April 2, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment March 27, 2026 View on SEC
4 Insider stock transaction report March 23, 2026 View on SEC
4 Insider stock transaction report March 23, 2026 View on SEC
4 Insider stock transaction report March 23, 2026 View on SEC
4 Insider stock transaction report March 23, 2026 View on SEC
4 Insider stock transaction report March 5, 2026 View on SEC
4 Insider stock transaction report March 5, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC

Annual Reports

10-K February 26, 2026
  • REPLIGEN is a vital partner in the bioprocessing industry, supplying essential tools for biologics and gene therapy development.
  • The company significantly expanded its strategic footprint in 2023 through multiple key acquisitions, including Flexbiosys, Metenova, Tantti, and Avitide.
View Analysis

Insider Trading

STRONG SELL 3 insiders 3 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.